Biofrontera Inc
Company Profile
Business description
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Contact
120 Presidential Way
Suite 330
WoburnMA01801
USAT: +1 781 245-1325
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
85
Stocks News & Analysis
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
stocks
These 2 ASX stocks look materially overvalued after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,809.20 | 9.60 | 0.11% |
CAC 40 | 8,042.19 | 13.29 | 0.17% |
DAX 40 | 22,148.03 | 110.20 | 0.50% |
Dow JONES (US) | 44,368.56 | 225.09 | -0.50% |
FTSE 100 | 8,807.44 | 30.05 | 0.34% |
HKSE | 22,191.01 | 333.09 | 1.52% |
NASDAQ | 19,649.95 | 6.10 | 0.03% |
Nikkei 225 | 39,574.68 | 610.98 | 1.57% |
NZX 50 Index | 12,905.98 | 7.97 | -0.06% |
S&P 500 | 6,051.97 | 16.53 | -0.27% |
S&P/ASX 200 | 8,545.50 | 10.20 | 0.12% |
SSE Composite Index | 3,342.22 | 4.17 | -0.12% |